NASDAQ:COAG Hemab Therapeutics (COAG) Stock Price, News & Analysis $25.89 0.00 (0.00%) As of 05/22/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesSEC FilingsTrendsBuy This Stock About Hemab Therapeutics Stock (NASDAQ:COAG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hemab Therapeutics alerts:Sign Up Key Stats Today's Range$25.21▼$27.0450-Day Range N/A52-Week Range$23.00▼$36.61Volume135,235 shsAverage Volume244,076 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options. Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders. The company’s work combines biology and translational research to advance potential therapies from discovery through clinical development. Based on publicly available information, Hemab Therapeutics is headquartered in the United States and operates as part of the broader global biopharmaceutical industry. The company’s leadership includes a management team with experience in drug development and hematology-focused research.AI Generated. May Contain Errors. Read More Receive COAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COAG Stock News HeadlinesHead to Head Analysis: Hemab Therapeutics (NASDAQ:COAG) and Prime Medicine (NASDAQ:PRME)May 24 at 4:47 AM | americanbankingnews.comHemab Therapeutics (NASDAQ:COAG) Major Shareholder Purchases $24,840.24 in StockMay 22, 2026 | insidertrades.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. | Porter & Company (Ad)Hemab Therapeutics Reports First Quarter 2026 Financial ResultsMay 21, 2026 | markets.businessinsider.comComparing Hemab Therapeutics (NASDAQ:COAG) & Prime Medicine (NASDAQ:PRME)May 21, 2026 | americanbankingnews.comRa Capital Management, L.P. Purchases 6,387 Shares of Hemab Therapeutics (NASDAQ:COAG) StockMay 15, 2026 | insidertrades.comRa Capital Management, L.P. Acquires 1,483 Shares of Hemab Therapeutics (NASDAQ:COAG) StockMay 12, 2026 | insidertrades.comRa Capital Management, L.P. Purchases 68,018 Shares of Hemab Therapeutics (NASDAQ:COAG) StockMay 7, 2026 | insidertrades.comSee More Headlines COAG Stock Analysis - Frequently Asked Questions How have COAG shares performed this year? Hemab Therapeutics' stock was trading at $34.00 at the start of the year. Since then, COAG shares have decreased by 23.9% and is now trading at $25.89. How were Hemab Therapeutics' earnings last quarter? Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) released its quarterly earnings results on Thursday, May, 21st. The company reported ($23.98) earnings per share (EPS) for the quarter. When did Hemab Therapeutics IPO? Hemab Therapeutics (COAG) raised $285 million in an initial public offering (IPO) on Friday, May 1st 2026. The company issued 16,750,000 shares at a price of $16.00-$18.00 per share. When does Hemab Therapeutics' quiet period expire? Hemab Therapeutics's quiet period expires on Wednesday, June 10th. Hemab Therapeutics had issued 16,750,000 shares in its initial public offering on May 1st. The total size of the offering was $301,500,000 based on an initial share price of $18.00. During Hemab Therapeutics' quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of Hemab Therapeutics? Shares of COAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/21/2026Today5/26/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Biological Products, Except Diagnostic Substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COAG CIK2114044 WebN/A Phone(452) 138-7627FaxN/AEmployees72Year Founded2019Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares44,193,000Free FloatN/AMarket Cap$1.14 billion OptionableN/A BetaN/A Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:COAG) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemab Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
